Cerenome, Inc.

Snapshot

Cerenome is a clinical-stage cancer company with a small but growing diagnostics business. FY 2025 revenue was $5.2M, down 10.5% YoY, while the net loss was $22.4M, more than four times revenue.

What's Happening Right Now

• Thu 29th Oct '26 · Trial enrollment: Cerenome completed enrollment in its Phase 2 ReSPECT-GBM trial of REYOBIQ in recurrent glioblastoma on Oct 29, 2026, with topline data expected mid-2027.
• Tue 27th Oct '26 · Conference data: Cerenome will present interim safety and biomarker data from the first 10 patients in its ReSPECT-LMM study at the SNO Annual Meeting, Nov 12-15, 2026.
• Thu 8th Oct '26 · Payer deal: Cerenome's CNSide Diagnostics signed an in-network agreement with Florida Blue effective Oct 1, 2026, bringing total contracted payer coverage to approximately 164 million lives.
• Tue 6th Oct '26 · Product launch: Cerenome's CNSide Diagnostics commercially launched two new CSF-based molecular profiling tests in the U.S. starting Oct 12, 2026, expanding beyond its original leptomeningeal metastases test.
• Thu 10th Sep '26 · Financing: On Sep 10, 2026, Cerenome entered a senior secured financing facility of up to $20 million with 3i, LP, structured with royalty-based repayments to fund CNSide commercial scale-up.
• Thu 10th Sep '26 · Offering: Raised $3.00M in gross proceeds through a private placement (PIPE), and a $3.19M convertible note.
• Tue 30th Jun '26 · ATM sale: Sold $1.80M net / 436K shares through its at-the-market program, as stated for Apr 1, 2026 to Jun 30, 2026.
• Tue 30th Jun '26 · ATM sale: Sold $1.80M net / 436K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.